Globus Medical’s (NYSE:GMED) Q3: Strong Sales, Stock Jumps 19.2%

Medical instrumentality institution Globus Medical (NYSE:GMED) announced better-than-expected gross successful Q3 CY2025, with income up 22.9% twelvemonth connected twelvemonth to $769 million. The company’s full-year gross guidance of $2.88 cardinal astatine the midpoint came successful 0.8% supra analysts’ estimates. Its non-GAAP nett of $1.18 per stock was 53.4% supra analysts’ statement estimates.

Is present the clip to bargain Globus Medical? Find retired successful our afloat probe report.

• Revenue: $769 cardinal vs expert estimates of $734.8 cardinal (22.9% year-on-year growth, 4.7% beat)

• Adjusted EPS: $1.18 vs expert estimates of $0.77 (53.4% beat)

• Adjusted EBITDA: $252.6 cardinal vs expert estimates of $198.4 cardinal (32.8% margin, 27.3% beat)

• The institution lifted its gross guidance for the afloat year to $2.88 cardinal astatine the midpoint from $2.85 billion, a 1.1% increase

• Management raised its full-year Adjusted EPS guidance to $3.80 astatine the midpoint, a 20.6% increase

• Operating Margin: 17.9%, up from 7.7% successful the aforesaid 4th past year

• Free Cash Flow Margin: 27.8%, up from 25.8% successful the aforesaid 4th past year

• Constant Currency Revenue roseate 22.3% twelvemonth connected twelvemonth (63.4% successful the aforesaid 4th past year)

• Market Capitalization: $8.31 billion

“We are pleased with the spot of our wide results and continued advancement passim the company,” commented Keith Pfeil, President and Chief Executive Officer.

With operations spanning 64 countries and a portfolio of implicit 10 caller products launched successful 2023 alone, Globus Medical (NYSE:GMED) develops and sells implantable devices, surgical instruments, and exertion solutions for spine, orthopedic, and neurosurgical procedures.

A company’s semipermanent income show tin bespeak its wide quality. Even a atrocious concern tin radiance for 1 oregon 2 quarters, but a top-tier 1 grows for years. Luckily, Globus Medical’s income grew astatine an exceptional 29.3% compounded yearly maturation complaint implicit the past 5 years. Its maturation bushed the mean healthcare institution and shows its offerings resonate with customers, a adjuvant starting constituent for our analysis.

We astatine StockStory spot the astir accent connected semipermanent growth, but wrong healthcare, a half-decade humanities presumption whitethorn miss caller innovations oregon disruptive manufacture trends. Globus Medical’s annualized gross maturation of 50.3% implicit the past 2 years is supra its five-year trend, suggesting its request was beardown and precocious accelerated.

We tin excavation further into the company’s income dynamics by analyzing its changeless currency revenue, which excludes currency movements that are extracurricular their power and not indicative of demand. Over the past 2 years, its changeless currency income averaged 58.8% year-on-year growth. Because this fig is amended than its mean gross growth, we tin spot that overseas speech rates person been a headwind for Globus Medical.